Under a new e-prescribing requirement, effective Jan. 1, 2022, all information concerning a prescription for controlled substances Schedule II – Schedule V, or information concerning a refill authorization for controlled substances Schedule III – Schedule V, must be communicated electronically unless one of the authorized exemptions are met, or the health care provider has obtained a waiver from the Department of Health (DOH).

Learn more about the new e-prescribing requirement and see a list of waiver qualifications on the WSDA Blog.

E-Prescribing Resources for WSDA Members

WSDA has partnered with two vendors, iCoreConnect and iPrescribe, to help members comply with the new e-prescribing requirement.

iCoreConnect, a WSDA Recommended Solution, develops cloud-based technologies to improve and protect your practice. WSDA members receive 43% off their iCoreRx subscription.

Visit land.icoreconnect.com/WA2 or call (888) 810-7706.

Learn More about iCoreConnect

iPrescribe is the #1 Electronic Prescribing app available today. iPrescribe provides prescribing of both controlled and standard medications; easy access to a patient’s medication history data; in-workflow checking of State’s prescription drug monitoring program (PDMP) database (where applicable); at-a-glance allergy and drug to drug alerts; and renewal requests on-the-go.

Through the partnership, association members can use the award-winning iPrescribe mobile app at no cost for the first year.

For more information, visit www.iPrescribe.com.

Learn More about iPrescribe

Questions? Please contact WSDA at info@wsda.org.